Arch Biopartners Inc V.ARCH

$4.44 - Extremely Undervalued in Comparison to peers

[Riverfolk]

The recent realization by the market has made the Arch chart look incredible, but lets no forget that we are extremely undervalued compared to our peer 

Current Market cap 275 mil US

We are waiting on Phase II Human Clinical Trial Data by a third party for a 20 billion a year unmet market.

BLU is currently 695 mil market cap for Chronic Cough (Phase 2)

VXRT is currently 888 mil market cap  US Oral Vaccines

SAVA is 2 billion US market cap for Blood Cancer (Phase 2)

CYDY is 1.1  billion US market cap for Antibodies

TRIL was 2.2 billion buyout (Phase 2)

As we wait on data, there is no reason why we are not at a 695 million market cap of $11.20. We have fully patented new mechanism of action with a drug library. IMHO we will be 10x this current price if data deems it worthy.

[SrPlata]

Let's go over the reasons we are so undervalued compared to other Phase 2 biotech companies. This is more for the Newbies to ARCH 1. Trading on the OTCQB and Toronto Venture Exchange (a lot of investors can't or won't buy on these exchanges) 2. They never took money from Wall St or Bay St so therefore no Wall St or Bay St analysts with Buy Recs on them. 3. No Liquidity to buy for any